Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

NCT00088881 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

62

Enrollment

NIH

Sponsor class

Conditions

Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Splenic Marginal Zone Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Testicular Lymphoma
Waldenström Macroglobulinemia

Interventions

BIOLOGICAL: rituximab
DRUG: prednisone
DRUG: cyclophosphamide
DRUG: doxorubicin
DRUG: vincristine
RADIATION: indium In 111 ibritumomab tiuxetan
RADIATION: radiation therapy
PROCEDURE: positron emission tomography

Sponsor

National Cancer Institute (NCI)